Daily Cardiology Research Analysis
Analyzed 131 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies span mechanistic-to-population science. An integrative Circulation study links seven exercise physiologic deficits in HFpEF to distinct metabolite and genetic signatures with prognostic value. A Hypertension mega-cohort shows adolescent blood pressure, especially diastolic, predicts cardiovascular events before age 50. A basic–translational Advanced Science paper identifies ELABELA as a mitochondrial regulator of fetal heart development and a potential prenatal biomarker/therapeutic target for congenital heart disease.
Research Themes
- HFpEF pathophysiology and multi-organ exercise phenotyping
- Life-course cardiovascular risk from adolescence
- Mitochondrial mechanisms and developmental cardiology
Selected Articles
1. Multi-Organ Physiologic Deficits During Exercise Identify Clinical and Molecular Predisposition to Heart Failure with Preserved Ejection Fraction.
An integrative analysis defined seven exercise physiologic deficits in HFpEF and linked each to distinct circulating metabolite signatures and long-term incident HF risk in MESA. Metabolite signatures mapped to tissue-specific genetic variation shared with HFpEF comorbidities, supporting metabolic pathways as mechanistic drivers and prognostic markers.
Impact: This work bridges invasive physiology with omics and population validation, offering a framework to subphenotype HFpEF with path to targeted trials.
Clinical Implications: Clinicians could use exercise-defined physiologic profiles and associated metabolite panels to stratify HFpEF risk, personalize therapy targets (e.g., peripheral extraction vs pulmonary vascular load), and design mechanism-based trials.
Key Findings
- Seven discrete exercise deficits (e.g., reduced stroke volume/chronotropic response, steep PCWP/CO slope, impaired peripheral O2 extraction) were delineated in HFpEF.
- Each deficit exhibited a specific circulating metabolite signature derived by LASSO and validated for associations with incident HF over ≈20 years in MESA (n=6,345).
- Metabolite signatures mapped to tissue-specific genetic variation shared with HFpEF comorbidities (obesity, renal disease, diabetes), linking physiology to molecular mechanisms and prognosis.
Methodological Strengths
- Integration of invasive CPET with metabolomics and genomics plus external validation in a large population cohort (MESA).
- Use of LASSO to derive physiologically anchored metabolite signatures and genetic mapping across large GWAS datasets.
Limitations
- Observational design limits causal inference; interventional validation is needed.
- iCPET cohort size and selection criteria are not detailed in the abstract; potential selection bias and multiple-testing burden.
Future Directions: Prospective trials targeting specific exercise deficits (e.g., improving peripheral extraction or RV-PA coupling) guided by metabolite/genetic signatures; development of clinically deployable metabolite panels.
BACKGROUND: Exercise unmasks limitations in multi-organ system reserve capacity characteristic of heart failure with preserved ejection fraction (HFpEF). However, the metabolic and genetic underpinnings of exercise deficits, and their cumulative contribution to HFpEF severity and prognosis, remain incompletely understood. METHODS: We used invasive cardiopulmonary exercise testing (iCPET), metabolite profiling, and genomics to simultaneously characterize seven exercise physiologic deficits in HFpEF patients: reduced exercise stroke volume and heart rate, steep pulmonary capillary wedge pressure/cardiac output (PCWP/CO) slope, elevated pulmonary vascular resistance, pulmonary mechanical limitation to exercise, impaired peripheral oxygen extraction, and obesity-related exaggerated metabolic cost of initiating exercise. We first mapped the distribution, functional, and prognostic significance of these exercise deficits. We then applied LASSO regression to identify metabolite signatures of each exercise deficit, and measured the relation of these signatures with clinical-demographic features, cardiac magnetic resonance imaging, and incident HF in 6345 individuals in the Multi-Ethnic Study of Atherosclerosis (MESA) study with ≈20-year follow-up. Finally, we mapped deficit-implicated metabolites to tissue-specific genetic variation in ≈2M individuals with HF, and in the largest genome-wide association study (GWAS) studies of HFpEF comorbidities (obesity, renal disease, diabetes) to evaluate shared metabolic mechanisms of HFpEF pathophysiology. RESULTS: Our iCPET HFpEF cohort (61.7±14.1 years, 54% female, BMI 30.6±6.7 kg/m CONCLUSIONS: Organ-specific responses to exercise and their circulating metabolite signatures are strongly linked to HFpEF development and prognosis. These results offer a paradigm for parsing HFpEF subphenotypes and prioritizing metabolic mechanisms of HFpEF.
2. ELABELA Targets Mitochondria to Modulate Heart Development.
ELA levels are reduced in human fetal CHD and in maternal plasma of CHD pregnancies. In mice, loss of ELA in cardiac progenitors impairs mitochondrial integrity via APJ–AKT–BCL2/BAX signaling, causing malformations; exogenous ELA mitigates CHD severity and incidence.
Impact: First mechanistic link between ELA, mitochondrial homeostasis, and cardiac morphogenesis with rescue by exogenous peptide suggests a biomarker and therapeutic avenue in fetal CHD.
Clinical Implications: ELA could serve as a prenatal biomarker to flag fetal CHD risk and, if safety is established, a candidate peptide therapy to prevent malformations by restoring mitochondrial signaling.
Key Findings
- ELA levels were significantly reduced in human fetal cardiac tissues with CHD and in maternal plasma of pregnancies with fetal CHD.
- Cardiac progenitor-specific ELA deletion in mice disrupted mitochondrial function via APJ–AKT–BCL2/BAX signaling, causing cardiac malformations.
- Exogenous ELA administration reduced both the severity and incidence of CHD in mouse models.
Methodological Strengths
- Cross-species evidence: human fetal tissue and maternal plasma corroborated by mouse genetic models.
- Mechanistic dissection of APJ–AKT–BCL2/BAX signaling with rescue experiments using exogenous peptide.
Limitations
- Predominantly preclinical; human interventional data are lacking.
- Dose, timing, and safety profile of ELA therapy in pregnancy require rigorous evaluation.
Future Directions: Prospective studies to validate maternal plasma ELA as a screening biomarker; preclinical toxicology, pharmacokinetics, and large-animal efficacy to support first-in-human prenatal trials.
Congenital heart disease (CHD) is a leading cause of neonatal morbidity and mortality, whose underlying pathogenesis remains largely unclear, and lacks reliable biomarkers or therapeutic targets for early detection and treatment during pregnancy. In this study, we investigated the role of endogenous peptide ELABELA (ELA) in fetal CHD. Our findings reveal that ELA levels are significantly reduced in human fetal cardiac tissues with CHD. In mouse models, ELA deletion in cardiac progenitor cells disrupted mitochondrial function, directly contributing to cardiac malformations. Mechanistically, ELA deficiency caused mitochondrial swelling by inhibiting the APJ-AKT-BCL2/BAX signaling pathway. Notably, exogenous ELA administration reduced both CHD severity and incidence in mice. Furthermore, plasma ELA levels were markedly down-regulated in human pregnancies with fetal CHD. These findings establish ELA as a crucial regulator of cardiac development and highlight its potential as both a biomarker and therapeutic target for the prevention and management of fetal CHD during gestation.
3. Adolescent Blood Pressure and Cardiovascular Disease Before Age 50 Years.
In 902,741 adolescents followed for >18 million person-years, higher adolescent BP across AAP categories predicted incident CVD before age 50, with stage 1 risk particularly sensitive to diastolic BP. Findings support guideline refinements to incorporate adolescent BP indices into early-life prevention.
Impact: The scale, standardized exposure categories, and hard outcomes provide compelling evidence to recalibrate adolescent BP thresholds for long-term cardiovascular prevention.
Clinical Implications: Earlier identification and management of elevated adolescent BP, with attention to diastolic BP even in stage 1, could attenuate early adult CVD; supports integrating adolescent BP into lifetime risk tools.
Key Findings
- Among 902,741 adolescents (16–19 years), 6,305 CVD events occurred over >18 million person-years (0.35/1000 person-years).
- Compared with normal BP, adjusted HRs for CVD were 1.14 for stage 1, 1.31 for stage 2, and 2.42 for clinically diagnosed hypertension.
- Stage 1 risk was particularly sensitive to diastolic BP, underscoring the prognostic relevance of DBP in youth.
Methodological Strengths
- Nationwide cohort with nearly one million adolescents and standardized AAP BP categorization.
- Extensive follow-up with hard clinical endpoints and multivariable confounder adjustment.
Limitations
- Observational design with potential residual confounding; BP measured at baseline, limited capture of longitudinal BP changes.
- Generalizability may be context-specific to the mandatory service population and healthcare system.
Future Directions: Integrate adolescent BP into lifetime risk calculators; evaluate interventions targeting diastolic BP in youth for prevention of early adult CVD.
BACKGROUND: Adolescent blood pressure guidelines rely on expert consensus because evidence on cardiovascular outcomes is limited. This study aimed to examine the link between adolescent blood pressure indices and early cardiovascular events. METHODS: We conducted a cohort study among 902 741 adolescents aged 16 to 19 years who were evaluated for mandatory service from 1979 to 2019, excluding those with preexisting cardiometabolic conditions. Individuals were followed until 50 or death or insurance loss or December 31, 2021, whichever occurred first. Exposures included baseline blood pressure and American Academy of Pediatrics categories: normal (<120/<80), elevated (120/<80-129/<80), stage 1 (130/80-139/89), stage 2 (≥140/90), and hypertension (clinical diagnosis). The primary outcome was incident cardiovascular events (ischemic heart disease or cerebrovascular disease). Hazard ratios were estimated using Cox models adjusted for demographic, socioeconomic, and clinical confounders. RESULTS: During over 18 million person-years of follow-up, 6305 cardiovascular disease events were recorded, yielding an incidence rate of 0.35 per 1000 person-years. Increased diastolic, systolic, and mean arterial blood pressure were significantly associated with increased risk. Compared with the Normal group, adjusted hazard ratios for cardiovascular disease were 1.14 (95% CI, 1.08-1.22) for stage 1, 1.31 (1.20-1.44) for stage 2, and 2.42 (1.87-3.12) for hypertension. Risk in the stage 1 category was particularly sensitive to diastolic blood pressure. CONCLUSIONS: Higher blood pressure indices during adolescence were strongly associated with an elevated risk of early cardiovascular disease, highlighting the potential need to refine current guidelines to better reflect cardiovascular risk.